Navigation Links
Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
Date:11/19/2012

PARSIPPANY, N.J., Nov. 19, 2012 /PRNewswire/ -- Validus Pharmaceuticals together with Wood Creek Capital Management, LLC announced today the acquisition of the U.S. rights to six well-known product lines from Novartis Pharmaceuticals Corporation (NPC): Lopressor® (metoprolol tartrate USP) but excluding Lopressor (metoprolol tartrate) Injection, Lopressor® HCT (metoprolol tartrate USP + hydrochlorothiazide USP), Lotensin® (benazepril HCl), Lotensin HCT® (benazepril HCl + hydrochlorothiazide USP), Parlodel® (bromocriptine mesylate USP) and Methergine® (methylergonovine maleate).

Wood Creek Capital Management acquired the NPC products on August 29, 2012 through a new company, US Pharmaceuticals Holdings I LLC. Validus Pharmaceuticals will serve as the exclusive manager for the ex-NPC lines. These products present Validus with opportunities to generate sales in several new therapeutic markets and represent a significant growth catalyst for the company.

"The management and marketing of these significant new product lines fulfills a major step in Validus Pharmaceuticals' strategic plan for continued growth," commented James Hunter, Validus CEO. "The company's life-cycle plan had called for the timely expansion of product offerings beyond our successful Central Nervous System and Renal product lines. Adding these Novartis-developed medications immediately enables Validus to serve additional large and growing markets, particularly Cardiovascular Health."

"The acquisition of U.S. rights to these Novartis Pharmaceuticals Corporation products illustrates our belief in and commitment to the mature branded pharmaceuticals market," says Brett Hellerman, Wood Creek CEO.  "This is another in a series of successful transactions completed with large pharmaceutical companies that demonstrates we are good deal partners.  We are excited about the potential for our strategy."

As manufacturing of these products transitions to Validus, the company is working rapidly in order to assure both physicians and patients of a continued product supply under their label. Validus will be communicating directly with distributors and prescribing physicians regarding the availability of all these products.

About Validus Pharmaceuticals
Validus Pharmaceuticals LLC is a Parsippany, New Jersey-based specialty pharmaceutical company focused on the acquisition, reformulation, and marketing of FDA-approved prescription products that satisfy unmet clinical needs.  To fulfill this mission, Validus seeks out and acquires marketed products that have well established safety profiles as well as significant clinical benefits. 

For additional information please visit www.validuspharma.com.

About Wood Creek Capital Management, LLC

Wood Creek Capital Management is an investment manager at the forefront of private assets investing.  Headquartered in New Haven, CT Wood Creek has $930 million of committed capital under management as of June 30, 2012.  Wood Creek is a leading investor in intangible assets including pharmaceutical brands. 

For additional information please visit www.woodcreekcap.com.


'/>"/>
SOURCE Validus Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):